GEN Exclusives

More »

GEN News Highlights

Back to Item »

Biovail Licenses Acadia's Late-Stage CNS Disease Drug with an Initial Fee of $30M

Deal is valued at $395 million and allows Biovail to develop the compound in three indications.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Genetics and Intelligence

Do you believe research on the genetics of intelligence can improve education?

More »